| Literature DB >> 28506237 |
Damjana Ključevšek1, Nina Emeršič2, Nataša Toplak2,3, Tadej Avčin2,3.
Abstract
BACKGROUNDS: The purpose of the study was to evaluate the clinical and magnetic resonance imaging (MRI) outcome of cervical spine arthritis in children with juvenile idiopathic arthritis (JIA), who received anti-TNFα early in the course of cervical spine arthritis.Entities:
Keywords: Anti-TNFα; Cervical spine arthritis; Juvenile idiopathic arthritis; Magnetic resonance; Outcome
Mesh:
Substances:
Year: 2017 PMID: 28506237 PMCID: PMC5433237 DOI: 10.1186/s12969-017-0173-1
Source DB: PubMed Journal: Pediatr Rheumatol Online J ISSN: 1546-0096 Impact factor: 3.054
Fig. 1MRI of cervical spine (patient #5) (T1 TSE FS axial with a contrast medium): a inital MRI showed an intense contrast enhancement of the thickened synovia in pre- and paradental space (white arrows), b follow-up MRI 6 months later showed a reduction of synovial thickening and a significantly less intense enhancement (white arrows)
Fig. 2MRI of cervical spine (patient #8)(T1 TSE FS sagittal with a contrast medium): a initial MRI (January, 2013) showed an intense contrast enhancement of a huge synovial thickening (white arrow) in predental space with a huge anterior atlanto-axial subluxation (aAAS)(black line, 13 mm) and a compression of the anterior liquor space, normal shape of the dens, b follow-up MR (January, 2014): the evaluation of the treatment with anti-TNFα showed a reduction of synovial thickening and a less intense contrast-enhancement and less significant aAAS, normal width of the anterior liquor space, but with initial morphological changes of the dens, c follow-up MRI (March, 2016): the evaluation of the treatment with anti-TNFα showed a significant reduction of synovial thickening in the predental space and aAAS, only patchy contrast enhancement, but with morphological changes of the dens and a thinned corticalis
Clinical and MRI examination data in patients with cervical spine involvement
| G | JIA | iMRI age (y) | Biologics | Treatment duration with biologics(y) | last MRI results | Clinical outcome | ||
|---|---|---|---|---|---|---|---|---|
| Inflam | Chronic changes | |||||||
| 1 | M | pJIA | 4.1 | ETA | 0.7 | no | no | no inflam. |
| 2 | F | pJIA | 7.6 | IFX | 1.8 | no | no | no inflam. |
| 3 | F | pJIA | 6.9 | ETA | 1 | no | no | no inflam. |
| 4 | F | oJIA | 3.2 | ETA | 2.8 | no | no | no inflam. |
| 5 | M | pJIA | 2.4 | IFX | 0.5 | peristent | no | Inflam. in 2 perif.joints |
| 6 | M | pJIA | 14.8 | IFX | 0.5 | persistent | no | LROM |
| 7 | F | jPsA | 3.6 | IFX | 2.1 | no | no | no treatment for 2.3y |
| 8.2 | IFX | 1.5 | no | no | LROM | |||
| 8 | F | pJIA | 8.7 | IFX | 3.5 | peristent | yes | LROM |
| 9 | F | oJIA | 15.1 | IFX | 1.2 | no | no | no inflam. |
| 10 | F | pJIA | 2.7 | ADA | 0.3 | no | no | LROM |
| 11 | F | oJIA | 14.6 | ADATOC | 0.4 | no | no | Inflam. in 1perif.joint |
| 12 | F | poJIA | 3.1 | IT | 0.5 | no | yes | no inflam. |
| 13 | F | poJIA | 4.8 | IT | 0.6 | no | no | no inflam. |
| 14 | F | pJIA | 2.5 | IT | 0.3 | no | no | no inflam. |
| 15 | M | pJIA | 4.2 | IT | 1.5 | no | yes | no treatment for 1.4y |
G gender, F female, M male, pJIA polyarticular juvenile idiopatic arthritis, oJIA extended oligoarthritis JIA, poJIA persistent oligoarthritis JIA, jPsA juvenile psoriatic arthritis, iMRI age of child when initial magnetic resonance imaging of cervical spine confirmed cervical spine arthritisBiologics, IFX infliximab, ETA etanercept, ADA adalimumab, and Anti IL-6, TOC tocilizumab, IT initial treatment with corticosteroids and methotrexate (MTX) received all children, duration of IT was written only in children with delay introduction of biologics Last MR: Inflam – no inflammation, persistent inflammation of cervical spine seen on last MRI, chronic changes - no chronic changes, yes- chronic changes seen on last MRI Clinical outcome: no inflammation – no inflammation in other peripheral joints, X periph.joints- number of peripheral joints presented with inflammation